

Request for Pre Authorisation for a PETCT or a PSMA scan

Hospital Details

Requesting Clinician										
Referring hospital name										
PETCT centre name										
PETCT contact										
PETCT centre telephone (+extn)										
PETCT centre fax										
PETCT centre email										

Patient Details

Name										
Date of Birth (must be an adult)										
Irish Life Health Membership Number										
Proposed date of treatment										

To be Completed by the Requesting Consultant

Indications for use:

Nature of symptoms being investigated										
Date of onset of symptoms										
Previous history and treatment of these or any related symptoms, including any investigations their dates and results (Please attach history)										
Is this treatment related to a Research Study?(Please tick)	Yes						No			

Please indicate Clinical reasons why a PETCT scan is being selected in preference to other diagnostic techniques				
How may a PETCT scan assist/change the future treatment of the member?				
Is any further treatment required?				
Please supply details of PETCT Scan to be performed and the relevant procedure code:				
Was patient transferred to this facility from another hospital for this scan? (Please tick)	Yes		No	
If yes please name this facility				
Date of last PETCT (if applicable)				
Name of PETCT centre where performed				

Please Attach Please confirm that the following are attached.	YES	NO
Recent Consultant reports on CT Scan		
Recent Consultant reports on MRI Scan		
Recent Consultant reports on Histology Tests		

Declaration

I/we confirm that all the details, answers and information given in this form are true, accurate and complete. I/we confirm that I/we am/are giving my/our permission to you to use the information I/we have given on this form for the purposes set out in the Irish Life Health Privacy Notice which can be found at <http://www.irishlifehealth.ie/privacy-and-legal/privacy-statement/>

Signature (requesting Consultant)				
Date:				

Irish Life Health PETCT Clinical Indicators (Please tick as appropriate)

Description	Diagnosis	Staging		Recurrence	Therapy Control	Pre Surgery Evaluation
		Nodal	Metastatic			
Code						
Lung Cancer (NSCLC) 7701 7702 7703		7701	7702	7703		
Lung Cancer (Small Cell)				7712	7713	
Solitary Pulmonary Nodule (SPN)	7720					
Pulmonary mass lesions – only those that are too risky to biopsy	7730					
Colorectal Cancer		7741	7742	7742		
Oesophageal Cancer	7750		7752	7753		
Pancreatic Cancer				7763		
Malignant Melanoma		7771	7772	7773		
Lymphoma – Hodgkin's		7781	7782	7783	7784	
Lymphoma – High Grade Non Hodgkins		7791	7792	7793	7794	
Lymphoma – Low Grade Non Hodgkins		7801	7802	7803	7804	
Head Cancer		7811	7812	7813	7814	
Neck Cancer		7821	7822	7823	7824	
Cervical Cancer – limited to suspected remote metastases based on other imaging techniques		7831	7832	7833		
Unknown Primary Tumour	7840					
Breast Cancer – (not for axillary node evaluation)		7851	7852	7853	7854	
Brain Tumour				7863		7875*
Ovarian Tumour & Cervical Cancer				7873		
Bone & Soft Tissue Tumour				7883		
Differentiated Thyroid Cancer			7892			
Alzheimers Dementia – only where CT/MRI are negative	7900					
Myocardial Viability	7905					
Cardiomyopathy – differential diagnosis	7910					
Focal/Temporal Lobe Epilepsy						7925
Testicular Cancer**						7945**

*Ovarian Cancer – Restaging of previously treated women with a rising CA125 level, who have a negative or equivocal conventional imaging CT or MRI

**Testicular Cancer – restaging of men with previously treated disease for the purpose of detecting residual disease suspected recurrence or to determine the extent of recurrence

Irish Life Health PMSA Clinical Indicators (Please tick as appropriate)

PSMA Gallium 68 PET-CT Scan Clinical Guidelines	
Biochemical recurrence after radical prostatectomy (PSA \geq 0.2ng/mL). 68Ga-PSMA is particularly useful in investigating patients with low PSA values between 0.2 and 10 ng/ml. In patients with PSA>5, or rapidly rising, 68Ga-PSMA should only be considered where conventional imaging has been performed and has been negative or equivocal.	
Biochemical recurrence after radical radiotherapy/brachytherapy (PSA nadir + 2ng/ml) in patients being considered for salvage therapy following negative or equivocal conventional imaging.	
Biochemical recurrence (PSA \geq2ng/ml) after surgery and salvage radiotherapy where there is intent for further salvage therapy (e.g. salvage lymphadenectomy, nodal RT, SABR) and conventional imaging has been negative or equivocal Non-routine	